title: Stakeholder perspectives on a risk-benefit framework for genetic testing.
abstract: A key to accelerating the appropriate integration of genomic applications into healthcare in the coming decades will be the ability to assess the tradeoffs between clinical benefits and clinical risks of genetic tests in a timely manner. Several factors limit the ability of stakeholders to achieve this objective, including the lack of direct evidence, the lack of a framework to quantitatively assess risk and benefit, and the lack of a formal analytic approach to assess uncertainty. We propose that a formal, quantitative risk-benefit framework may be particularly useful for assessing genetic tests intended to influence health outcomes, and communicating the potential clinical benefits, harms, and uncertainty to stakeholders. As part of the development process for such a framework, a stakeholder meeting was held in Seattle (Wash., USA) in December of 2008, with the objective of discussing a risk-benefit framework, using warfarin pharmacogenomics as a case study. Participants engaged in focused discussion to elucidate the potential role of genetic test risk-benefit analysis in informing decision-making, categorizing genetic tests and directing research prioritization. This research investigation focuses on qualitative analysis of responses elicited from workshop participants during the proceedings of the workshop session. The major findings of the workshop were: (1) stakeholder support for risk-benefit modeling as a tool to structure discussion of the clinical utility of genetic tests; (2) desire for the modeling process to be iterative, transparent, and parsimonious in its presentation to stakeholders, and (3) some concern with the use of quality-adjusted life-years in the evaluation process. The meeting's findings emphasize the potential utility of risk-benefit analysis in genetic test evaluation, and highlight key areas for future research and stakeholder consensus-building.
authors.affiliation: Department of Pharmacy, University of Washington, Seattle, WA 98195, USA.
authors.forename: Joshua A
authors.initials: JA
authors.lastname: Roth
authors.forename: Louis P
authors.initials: LP
authors.lastname: Garrison
authors.forename: Wylie
authors.initials: W
authors.lastname: Burke
authors.forename: Scott D
authors.initials: SD
authors.lastname: Ramsey
authors.forename: Rick
authors.initials: R
authors.lastname: Carlson
authors.forename: David L
authors.initials: DL
authors.lastname: Veenstra
mesh_terms: D005820:Genetic Testing / Q000379:methods*; D023281:Genomics; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D019057:Quality-Adjusted Life Years; D018570:Risk Assessment; D013678:Technology, Pharmaceutical / Q000379:methods; D035501:Uncertainty; D014859:Warfarin / Q000494:pharmacology
chemical_list: D014859:Warfarin
references.citation: Nat Rev Genet. 2009 Jul;10(7):489-95
references.pmid: 19506575
references.citation: Thromb Haemost. 2004 Jan;91(1):87-94
references.pmid: 14691573
references.citation: Am J Med. 2005 Mar;118(3):251-8
references.pmid: 15745723
references.citation: Value Health. 2009 Mar;12 Suppl 1:S38-9
references.pmid: 19250131
references.citation: Circulation. 2007 Nov 27;116(22):2563-70
references.pmid: 17989110
references.citation: Health Aff (Millwood). 2007 May-Jun;26(3):684-95
references.pmid: 17485745
references.citation: N Engl J Med. 2005 Jun 2;352(22):2285-93
references.pmid: 15930419
references.citation: Clin Pharmacol Ther. 2008 Feb;83(2):312-21
references.pmid: 17653141
references.citation: Genet Med. 2009 Aug;11(8):575-6
references.pmid: 19623080
references.citation: Am J Manag Care. 2004 May;10(5):301-4
references.pmid: 15152698
references.citation: Clin Pharmacol Ther. 2008 Sep;84(3):303-5
references.pmid: 18714318
references.citation: Genet Med. 2009 Jan;11(1):66-73
references.pmid: 19125125
references.citation: Value Health. 2010 Jan-Feb;13(1):8-13
references.pmid: 19883405
references.citation: Qual Health Res. 2005 Nov;15(9):1277-88
references.pmid: 16204405
references.citation: Value Health. 2009 Mar;12 Suppl 1:S36-7
references.pmid: 19250130
references.citation: Health Aff (Millwood). 2009 Sep-Oct;28(5):1366-71
references.pmid: 19738253
references.citation: Pharmacogenetics. 2004 Aug;14(8):539-47
references.pmid: 15284536
references.citation: J Child Fam Nurs. 1999 Sep-Oct;2(5):388-90
references.pmid: 10795196
references.citation: Pharmacoeconomics. 2010;28(1):61-74
references.pmid: 20014877
references.citation: Value Health. 2009 Mar;12 Suppl 1:S27-30
references.pmid: 19250128
references.citation: Clin Pharmacol Ther. 2008 Sep;84(3):301-3
references.pmid: 18714317
references.citation: Ann Intern Med. 2009 Feb 3;150(3):199-205
references.pmid: 19189910
references.citation: Health Serv Res. 2000 Dec;35(5 Pt 3):128-40
references.pmid: 16148957